跳至主要内容
临床试验/NCT00090688
NCT00090688撤回1 期

Safety and Immunogenicity of Oral Microencapsulated CS6 Vaccine and LT(R192G) Adjuvant in Volunteers

U.S. Army Medical Research and Development Command1 个研究点 分布在 1 个国家开始时间: 2004年8月1日最近更新:
适应症

试验速览

阶段
1 期
状态
撤回
发起方
试验地点
1
主要终点
Systemic Immunogenicity

研究概览

简要总结

The study will enroll approximately 60 volunteers. The vaccine is given as a drink in flavored soda water. Volunteers will either receive a 3-dose vaccination with doses spaced two weeks apart or a 4-dose vaccination with doses spaced 2 days apart depending upon their availability for follow-up.

Once assigned to a vaccination schedule, volunteers will be randomly assigned to receive the meCS6 vaccine with or without the mLT adjuvant for all vaccine doses. Neither the study investigators nor the volunteers will know which group they are assigned.

Volunteers will be asked to be available for clinic visits and telephone follow-ups during the study period and provide blood and stool specimens for testing.

详细描述

The Phase 1 section of this study is a randomized double blind trial in which a total of 60 subjects (minimum of 52 allowable) will receive on of two oral vaccine doses according to the following chart:

Group Subset N CS6(Encapsulated) LT(R192G) I A 15 0.95mg 2 micrograms II B 15 0.95mg -- III A 15 0.95mg 2 micrograms IV B 15 0.95mg --

*minimum of 13 volunteers/group

Volunteers in Group I will receive three immunizations (study days 0, 14, and 28) during the vaccine series. Volunteers in Group II will receive four immunizations (study days 0, 2, 4, and 6) during the vaccine series. The two groups will be vaccinated separately for logistical purposes. Blood and stool specimens will be collected at intervals to examine systemic and mucosal vaccine antigen-specific immune responses. Vaccine safety will be actively evaluated during vaccination and for 4 weeks following the final vaccine dose.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Available for required follow-up period
  • •Women must have a negative pregnancy test
  • •Women must not to try to become pregnant while on study and for 2 months after study is completed

排除标准

  • •History of travellers' diarrhea
  • •Occupation that involves handling of E. coli or cholera bacteria, or E. coli vaccine
  • •Regular use of anti-diarrheal, anti-constipation, or antacid therapy
  • •Abnormal bowel habits
  • •Pregnant or nursing women
  • •History of chronic gastrointestinal illness or major gastrointestinal surgery
  • •Allergies to vaccines
  • •Positive HIV, Hepatitis B or Hepatitis C tests
  • •Regular use of oral steroid medication
  • •Clinically significant abnormalities on physical examination

结局指标

主要结局

Systemic Immunogenicity

Mucosal Immunogenicity

Safety

次要结局

未报告次要终点

研究者

发起方
U.S. Army Medical Research and Development Command
申办方类型
Fed

研究点 (1)

Loading locations...

相似试验